Install
Biotech
Biotechnology, gene editing, biopharma platforms, and clinical pipelines.
- 9 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
- Aerospace
- Agriculture
- Banking (Industry)
- Computing
- Consumer Goods
- Defense
- Energy & Utilities
- Entertainment
- Food & Beverage
- Government
- Healthcare
- Real Estate (Commercial)
- Management & Consulting
- Manufacturing
- Technology
- Telecom
- Transportation & Logistics
- Automotive
- Construction
- Education & EdTech
- Hospitality & Travel
- Insurance (Industry)
- Mining & Materials
- Pharmaceuticals
Latest in Biotech
Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery - AOL
58+ min ago (184+ words) AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it has signed an agreement for a research collaboration led by Alice Stanton, PhD from Massachusetts General Hospital (MGH)…...
Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery
58+ min ago (231+ words) Eagle-Tribune Aptar and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Sep 14, 2026-- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer…...
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029
2+ hour, 28+ min ago (257+ words) Labcorp Holdings on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day. The health care company emphasized its innovation roadmap, technological advancements and solid financial expectations for the coming years. The company validated its full-year…...
ALXO: Lead assets advance toward phase III, with strong biomarker focus and robust financial runway
2+ hour, 6+ min ago (71+ words) TradingView ALXO: Lead assets advance toward phase III, with strong biomarker focus and robust financial runway Two lead programs are advancing toward pivotal studies, with evorpacept showing strong biomarker-driven efficacy and ALX2004 progressing through dose escalation in multiple tumor types. Financial…...
CRSP: CASGEVY and three late-stage assets drive growth, with pivotal data and global expansion ahead
3+ hour, 16+ min ago (79+ words) TradingView CASGEVY’s pediatric label expansion and strong payer coverage are driving rapid revenue growth, while three key assets—CTX310, zugo-cel, and CTX611—are advancing toward pivotal trials. The pipeline is supported by robust research, AI-driven productivity, and a focus on global expansion…...
Sanofi divesting older medicines, trio of manufacturing sites | Monroe County Area
6+ hour, 7+ min ago (271+ words) PARIS- Biopharma giant Sanofi will unload three manufacturing sites as part of a new partnership. Its Swiftwater campus in Monroe County is not among those sites. Sanofi, headquartered in Paris, France, announced on Monday that it had reached an agreement…...
Veracyte acquiring Convergent Genomics in up to $180M deal
1+ hour, 25+ min ago (22+ words) Veracyte to buy Convergent for $150M upfront, gaining UroAmp MRD urine test for early bladder cancer detection and monitoring. Read more here....
Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push And Sepranolone Advancement
23+ hour, 9+ min ago (154+ words) Relmada Therapeutics is rated Hold as NVD-01 IND slips to 2026 despite strong NMIBC data; cash runway to 2029. Click here to read my latest analysis on RLMD stock. - Relmada Therapeutics is initiated at "Hold" due to delayed IND filing for lead…...
We're turning into a more innovative company: Teva Pharmaceuticals CEO Richard Francis
2+ hour, 59+ min ago (39+ words) Richard Francis, Teva Pharmaceuticals CEO short and pro, joins 'Power Lunch' to discuss the company's turnaround strategy, expanding its market access, its next growth leg, and more. We're turning into a more innovative company: Teva Pharmaceuticals CEO Richard Francis...
Cellectis Exits Two CAR-T Programs, Advances Gene Editing
21+ hour, 18+ min ago (140+ words) Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise → © OpenServe Holdings LLC Where do you stand? What each side asserts, disputes — or leaves out entirely. Whose framing of this story rings truest to…...